CIP
ADAP

Convergence Investment Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Convergence Investment Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-350
Closed -$4K – 309
2018
Q1 		$4K Buy
+350
New +$3.06K ﹤0.01% 858

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Convergence Investment Partners's ADAP Position: Q2 2018 in Review

Convergence Investment Partners sold out of Adaptimmune Therapeutics (ADAP) in Q2 2018, closing a stake of 350 shares — an estimated $4K sold.

Convergence Investment Partners first reported a position in ADAP in Q1 2018 and held it in 1 quarter. The position peaked at $4K in Q1 2018. 86 funds tracked by Wall St. Rank hold ADAP as of Q2 2018.

  • Convergence Investment Partners reported no remaining Adaptimmune Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Convergence Investment Partners sold 350 Adaptimmune Therapeutics shares in Q2 2018, an estimated $4K.
  • Convergence Investment Partners first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 1 quarter.
  • Convergence Investment Partners's Adaptimmune Therapeutics position peaked at $4K in Q1 2018.
  • 86 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2018.

Based on Convergence Investment Partners's 13F filing for Q2 2018, filed 7 Aug 2018.